Furnam, W.L., Crews, K.R., Billups, C., Wu, J., Gajjar, A.J., Daw, N.C., Patrick, C.C., Rodriguez-Galindo, C., Stewart, C.F., Dome, J.S., Panetta, J.C., Houghton, P.J. and Santana, V.M. (2006) Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients with Refractory Solid Tumours. Journal of Clinical Oncology, 24, 563-570. http://dx.doi.org/10.1200/JCO.2005.03.2847

has been cited by the following article:

• TITLE: Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects

  AUTHORS: Rachel M. McQuade, Joel C. Bornstein, Kulmira Nurgali

  KEYWORDS: Oxaliplatin; Irinotecan, 5-Fluorouracil, Cisplatin, Carboplatin, Chemotherapy, Colorectal Cancer, Chemotherapy-Induced Diarrhoea

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.7, April 14, 2014

  ABSTRACT: Chemotherapy-induced diarrhoea (CID) is a common side-effect experienced by patients being treated with a variety of antineoplastic agents. Approximately 80% of patients undergoing chemotherapeutic treatment for colorectal and other gastrointestinal cancers present with CID; moreover, about 5% of early deaths associated with combination anti-cancer chemotherapy are due to CID. Chronic post-treatment diarrhoea amongst cancer survivors can persist for more than 10 years greatly effecting long-term quality of life. Gastrointestinal toxicities such as diarrhoea and vomiting are amongst the primary contributors to dose reductions and delays throughout anti-cancer treatment, presenting a significant hurdle in clinical management of anti-cancer regimes and often result in sub-optimum treatment. However, little is known about pathophysiological mechanisms underlying CID. This work provides a review of chemotherapy-induced diarrhoea, current management guidelines, and shortcomings of current treatments as well as emerging and already existing anti-diarrhoeal treatments potentially suitable for CID.